Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Asset Writedowns and Impairment (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $87000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $87000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $676000.0, a N/A change, with the full-year FY2023 number at $2000.0, down 99.97% from a year prior.
  • Asset Writedowns and Impairment was $87000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $589000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $589000.0 in Q1 2025 to a low of $87000.0 in Q3 2025.